Table 2.
Baseline characteristics of all patients in the external cohort
| N=108 | |
| Age (years) | 73 (68, 78) |
| Gender, women | 20 (18.5) |
| Race, non-white | 29 (26.9) |
| Body mass index (kg/m2) | 26.1±3.2 |
| Comorbid disease | |
| Smoking status ever | 76 (70.4) |
| Diabetes mellitus | 23 (21.3) |
| Hypertension | 42 (38.9) |
| Cardiovascular disease | 44 (40.7) |
| Severe OSA | 17 (15.7) |
| Lung cancer | 4 (3.7) |
| Measures of IPF severity and management considerations | |
| FVC (%) predicted | 81.0±19.5 |
| FEV1/FVC (%) | 83.0 (79.0, 86.0) |
| DLCO (%) predicted | 47.4±15.7 |
| DLCO not performed | 3 (2.8) |
| 6MWD (m) | 473 (430, 559) |
| Surgical lung biopsy | 21 (19.4) |
| Antifibrotic therapy* | 67 (62.0) |
| Pirfenidone | 32 (29.6) |
| Nintedanib | 50 (46.3) |
| Exertional hypoxia | 45 (42.1) |
| Prescribed oxygen | 36 (33.3) |
| Observed desaturation† | 9 (8.3) |
| GAP stage‡ | |
| 1 | 43 (39.8) |
| 2 | 49 (45.4) |
| 3 | 16 (14.8) |
Data presented as mean±SD, median (25th percentile, 75th percentile) or n (%).
Most patients in this cohort were classified by the GAP index as having stage I (39.8%) or stage II (45.4%) disease.
*Antifibrotic therapy for at least 6 months (some patients transitioned between therapies).
†Observed desaturation during 6 min walk test in the absence of a prior oxygen prescription.
‡GAP stage as classified by the original GAP index proposed and validated by Ley et al. 5
DLCO, diffusion capacity for carbon monoxide; FEV1, forced expiratory volume in the first second; FVC, forced vital capacity; GAP, gender-age-physiology; 6MWD, 6 min walk distance.